Abstract
Radionuclide labeled leukocyte studies are routinely performed in the evaluation of patients with fever of unknown origin and occult infections. Cerebral perfusion agent Tc99m hexamethylpropyleneamine oxime (Tc99m — HMPAO) is one of the radiopharmaceuticals widely used for labeling of mixed leukocytes. It is a lipophilic agent which crosses cell membranes readily and preferentially labels granulocytes. This mechanism is used for labeling of leukocytes. Tc99m labeled leukocytes normally accumulate in spleen by sequestration. At sites of acute infection, focal increased radiotracer labeled leukocyte uptake is seen. Hence, focal defects in spleen represent infarcts. We present in this report two cases of splenic infarct diagnosed by Tc99m HMPAO labeled leukocytes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
